Blueprint Medicines/$BPMC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Ticker
$BPMC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
685
ISIN
US09627Y1091
Website
BPMC Metrics
BasicAdvanced
$6.5B
-
-$2.45
0.75
-
Price and volume
Market cap
$6.5B
Beta
0.75
52-week high
$121.90
52-week low
$73.04
Average daily volume
851K
Financial strength
Current ratio
2.802
Quick ratio
2.618
Long term debt to equity
171.829
Total debt to equity
208.496
Interest coverage (TTM)
-2.16%
Management effectiveness
Return on assets (TTM)
-9.75%
Return on equity (TTM)
-47.71%
Valuation
Price to revenue (TTM)
11.332
Price to book
18.94
Price to tangible book (TTM)
18.94
Price to free cash flow (TTM)
-42.212
Growth
Revenue change (TTM)
99.19%
Earnings per share change (TTM)
-48.18%
3-year revenue growth (CAGR)
36.46%
3-year earnings per share growth (CAGR)
-39.46%
What the Analysts think about BPMC
Analyst ratings (Buy, Hold, Sell) for Blueprint Medicines stock.
BPMC Financial Performance
Revenues and expenses
BPMC Earnings Performance
Company profitability
BPMC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Blueprint Medicines stock?
Blueprint Medicines (BPMC) has a market cap of $6.5B as of May 23, 2025.
What is the P/E ratio for Blueprint Medicines stock?
The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of May 23, 2025.
Does Blueprint Medicines stock pay dividends?
No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Blueprint Medicines dividend payment date?
Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.
What is the beta indicator for Blueprint Medicines?
Blueprint Medicines (BPMC) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.